Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sana Intidhar Labidi-Galy

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Frontiers in Oncology|September 18, 2025
Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapyOraianthi Fiste, Michalis Liontos, Sana Intidhar Labidi-Galy
Swiss Medical Weekly|April 5, 2024
Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective studyCéline Py, Claudio De Vito, Petros Tsantoulis, et al.
Cancer Treatment Reviews|July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsHélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
Bulletin Du Cancer|January 20, 2012
First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancerJulien Peron, Olivier Tredan, Isabelle Ray-Coquard, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 22, 2024
Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapyValentina D'Atri, Guillaume Galy, Mathias Buff, et al.
Oncoimmunology|June 28, 2012
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosisSana Intidhar Labidi-Galy, Isabelle Treilleux, Sophie Goddard-Leon, et al.
Expert Opinion on Pharmacotherapy|September 15, 2011
Therapeutic pipeline for soft-tissue sarcomaPhilippe A Cassier, Sana Intidhar Labidi-Galy, Pierre Heudel, et al.
Journal of Translational Medicine|October 4, 2017
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerAlberto Ballestrero, Davide Bedognetti, Domenico Ferraioli, et al.
Breast Cancer Research and Treatment|December 25, 2010
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, et al.
International Journal of Cancer|February 8, 2013
Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cellsVanja Sisirak, Nelly Vey, Nadège Goutagny, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|September 18, 2025
Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapyOraianthi Fiste, Michalis Liontos, Sana Intidhar Labidi-Galy
Swiss Medical Weekly|April 5, 2024
Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective studyCéline Py, Claudio De Vito, Petros Tsantoulis, et al.
Cancer Treatment Reviews|July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsHélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
Bulletin Du Cancer|January 20, 2012
First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancerJulien Peron, Olivier Tredan, Isabelle Ray-Coquard, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 22, 2024
Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapyValentina D'Atri, Guillaume Galy, Mathias Buff, et al.
Oncoimmunology|June 28, 2012
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosisSana Intidhar Labidi-Galy, Isabelle Treilleux, Sophie Goddard-Leon, et al.
Expert Opinion on Pharmacotherapy|September 15, 2011
Therapeutic pipeline for soft-tissue sarcomaPhilippe A Cassier, Sana Intidhar Labidi-Galy, Pierre Heudel, et al.
Journal of Translational Medicine|October 4, 2017
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerAlberto Ballestrero, Davide Bedognetti, Domenico Ferraioli, et al.
Breast Cancer Research and Treatment|December 25, 2010
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, et al.
International Journal of Cancer|February 8, 2013
Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cellsVanja Sisirak, Nelly Vey, Nadège Goutagny, et al.
Pageof 2